Mark W. Kieran researcher
Kieran, Marc
VIAF ID: 540144782716878103945 (Personal)
Permalink: http://viaf.org/viaf/540144782716878103945
Preferred Forms
- 100 1 _ ‡a Kieran, Marc
- 100 0 _ ‡a Mark W. Kieran ‡c researcher
4xx's: Alternate Name Forms (2)
Works
Title | Sources |
---|---|
Genomic Profiling of Pediatric Low-Grade Gliomas | |
Metachronous mediastinal seminoma occurring after intracranial germinoma in an adolescent | |
Metronomic antiangiogenic therapy in children with recurrent brain tumours of different histologies | |
Microbiome at sites of gingival recession in children with Hutchinson-Gilford progeria syndrome. | |
Mitogenic and progenitor gene programmes in single pilocytic astrocytoma cells | |
Molecular aspects, clinical aspects and possible treatment modalities for Costello syndrome: Proceedings from the 1st International Costello Syndrome Research Symposium 2007 | |
Moyamoya following cranial irradiation for primary brain tumors in children. | |
MR Imaging Correlates for Molecular and Mutational Analyses in Children with Diffuse Intrinsic Pontine Glioma | |
Multiparametric Analysis of Permeability and ADC Histogram Metrics for Classification of Pediatric Brain Tumors by Tumor Grade. | |
Multiplexed Immunofluorescence Reveals Potential PD-1/PD-L1 Pathway Vulnerabilities in Craniopharyngioma. | |
MYB-QKI rearrangements in angiocentric glioma drive tumorigenicity through a tripartite mechanism | |
Myelopoiesis in the zebrafish, Danio rerio. | |
Myxopapillary ependymomas in children: imaging, treatment and outcomes | |
Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma | |
Neuropsychological functioning after surgery in children treated for brain tumor. | |
Neutralization of Circulating Vascular Endothelial Growth Factor (VEGF) by Anti-VEGF Antibodies and Soluble VEGF Receptor 1 (sFlt-1) Induces Proteinuria | |
New approaches to progeria | |
New Classification for Central Nervous System Tumors: Implications for Diagnosis and Therapy | |
Next generation metronomic chemotherapy-report from the Fifth Biennial International Metronomic and Anti-angiogenic Therapy Meeting, 6-8 May 2016, Mumbai. | |
NF1 plexiform neurofibroma growth rate by volumetric MRI: relationship to age and body weight. | |
NS-26THE ROLE OF SURGERY IN NON-NF-ASSOCIATED PEDIATRIC OPTIC PATHWAY GLIOMAS (OPG) - IS THERE A NEW PARADIGM? | |
Ophthalmologic Features of Progeria | |
Outcome of pediatric pineoblastoma after surgery, radiation and chemotherapy. | |
Paediatric Strategy Forum for medicinal product development of epigenetic modifiers for children: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration | |
Parent-perceived child cognitive function: results from a sample drawn from the US general population | |
PATH-17. INCREASING VALUE OF AUTOPSIES IN PATIENTS WITH BRAIN TUMORS IN THE MOLECULAR ERA | |
Paucicellular Fibrointimal Proliferation Characterizes Pediatric Pulmonary Vein Stenosis: Clinicopathologic Analysis of 213 Samples From 97 Patients | |
PDCT-03. PHASE 1 STUDY OF Ad-RTS-hIL-12 + VELEDIMEX IN PEDIATRIC BRAIN TUMORS | |
PDCT-24. A PHASE I DOSE ESCALATION TRIAL OF THE MEK1/2 INHIBITOR MEK162 (BINIMETINIB) IN CHILDREN WITH LOW-GRADE GLIOMAS AND OTHER RAS-RAF PATHWAY-ACTIVATED TUMORS: INITIAL REPORT | |
PDTM-04. REDEFINING THE CELLULAR ARCHITECTURE OF DIFFUSE MIDLINE GLIOMAS WITH H3 K27M MUTATIONS THROUGH LARGE-SCALE SINGLE-CELL ANALYSES | |
PDTM-06. ALK AMPLIFICATION AND REARRANGEMENTS ARE RECURRENT TARGETABLE EVENTS IN GLIOBLASTOMA | |
Pediatric brainstem gliomas: new understanding leads to potential new treatments for two very different tumors. | |
Pediatric cancer research: Surviving COVID-19 | |
Pediatric high-grade glioma: biologically and clinically in need of new thinking | |
Pediatric neuro-oncology: current status and future directions. | |
A Phase I and Pharmacokinetic Study of Oral Dabrafenib in Children and Adolescent Patients with Recurrent or Refractory BRAF V600 Mutation-Positive Solid Tumors | |
Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a Pediatric Brain Tumo | |
Phase I clinical trial of mafosfamide in infants and children aged 3 years or younger with newly diagnosed embryonal tumors: a pediatric brain tumor consortium study | |
PHASE I INDIVIDUAL DOSE TITRATION TRIAL OF THE HUMAN CORTICOTROPIN-RELEASING FACTOR (HCRF), CORTICORELIN ACETATE INJECTION (XERECEPT) IN PEDIATRIC PATIENTS WITH PERITUMORAL EDEMA OF THE BRAIN. | |
Phase I study of oral sonidegib (LDE225) in pediatric brain and solid tumors and a phase II study in children and adults with relapsed medulloblastoma. | |
Phase I study of SU5416, a small molecule inhibitor of the vascular endothelial growth factor receptor (VEGFR) in refractory pediatric central nervous system tumors | |
A phase I trial of etanidazole and hyperfractionated radiotherapy in children with diffuse brainstem glioma | |
Phase II study of cilengitide in the treatment of refractory or relapsed high-grade gliomas in children: a report from the Children's Oncology Group | |
Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults. | |
Phase II study of thalidomide and radiation in children with newly diagnosed brain stem gliomas and glioblastoma multiforme. | |
A phase II trial of a multi-agent oral antiangiogenic | |
Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas. | |
Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma | |
A pilot study of dose-intensified procarbazine, CCNU, vincristine for poor prognosis brain tumors utilizing fibronectin-assisted, retroviral-mediated modification of CD34+ peripheral blood cells with O6-methylguanine DNA methyltransferase | |
Pilot study of systemic and intrathecal mafosfamide followed by conformal radiation for infants with intracranial central nervous system tumors: a pediatric brain tumor consortium study (PBTC-001) | |
Platelets actively sequester angiogenesis regulators | |
Portohepatic shunt in a Down syndrome patient with an interchange trisomy 47,XY,-2,+der(2),+der(21)t(2;21)(p13;q22.1)mat | |
PPARalpha agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition. | |
PPARalpha deficiency in inflammatory cells suppresses tumor growth | |
PPARgamma as a therapeutic target for tumor angiogenesis and metastasis | |
PPARs: A Double-Edged Sword in Cancer Therapy? | |
PPM1D mutations are oncogenic drivers of de novo diffuse midline glioma formation | |
Predictors of neoplastic disease in children with isolated pituitary stalk thickening. | |
Preoperative stimulation of resolution and inflammation blockade eradicates micrometastases | |
Proceedings from the 2009 genetic syndromes of the Ras/MAPK pathway: From bedside to bench and back. | |
Profiling critical cancer gene mutations in clinical tumor samples | |
Prognostic value of tumor microinvasion and metalloproteinases expression in intracranial pediatric ependymomas | |
A prospective, blinded analysis of A-PROTEIN (recoverin or CAR protein) levels in pediatric patients with central nervous system tumors. | |
Prospective Feasibility and Safety Assessment of Surgical Biopsy for Patients with Newly Diagnosed Diffuse Intrinsic Pontine Glioma. | |
A prospective phase II trial of vinblastine and methotrexate in multivessel intraluminal pulmonary vein stenosis in infants and children | |
A prospective study of radiographic manifestations in Hutchinson-Gilford progeria syndrome | |
Proteomic profiling of cerebrospinal fluid identifies prostaglandin D2 synthase as a putative biomarker for pediatric medulloblastoma: A pediatric brain tumor consortium study | |
Psychosocial and behavioral functioning among pediatric brain tumor survivors. | |
Pubertal Progression in Adolescent Females with Progeria. | |
Pulmonary vein stenosis: expression of receptor tyrosine kinases by lesional cells | |
QOL-28. CUTANEOUS REACTIONS TO TARGETED THERAPIES IN CHILDREN WITH CNS TUMORS: A CROSS-SECTIONAL STUDY | |
Quantification of water diffusion and relaxation times of human U87 tumors in a mouse model. | |
Recurrence after gross-total resection of low-grade pediatric brain tumors: the frequency and timing of postoperative imaging. | |
Recurrent ascites in a patient with low-grade astrocytoma and ventriculo-peritoneal shunt treated with the multikinase inhibitor sorafenib. | |
Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma | |
A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. | |
A small-molecule IAP inhibitor overcomes resistance to cytotoxic therapies in malignant gliomas in vitro and in vivo |